News
Ono enters license agreement with Ionis for polycythemia vera treatment sapablursen
Ono Pharmaceutical has entered into a license agreement with Ionis Pharmaceuticals for sapablursen, an investigational RNA-targeted medicine for the treatment of polycythemia vera (PV).
Sapablursen...
ONCOVITA and UNITHER Pharmaceuticals to develop new prophylactic vaccine based on Measovir and Euroject...
ONCOVITA, a biotechnology company specializing in innovative vaccine development and a spin-off from the Institut Pasteur, and UNITHER Pharmaceuticals, a global leader in sterile...
Bristol Myers Squibb receives European Commission approval for Opdivo plus Yervoy for the first-line...
The European Commission (EC) has approved Bristol Myers Squibb's Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma...
